GHRP-2 Half-Life & Stability
Part of the full GHRP-2 guide - a synthetic hexapeptide growth hormone secretagogue reference compound, identity-verified with a COA on every vial.
In brief
Pharmacokinetic and stability questions about GHRP-2 sit at the boundary between what the provided record specifies and what general peptide-class principles allow us to say. The entry catalogs a pharmacokinetic and pharmacodynamic characterization of GHRP-2 among its citations (Pihoker et al., JCEM 1998), but no numerical half-life, clearance, or degradation-rate value is provided in the data; this section therefore frames stability in general terms wherever a peptide-specific number is absent. What the structural data does tell us is meaningful: GHRP-2 is a short hexapeptide deliberately built with non-natural D-amino acids, an architecture associated across the secretagogue class with resistance to enzymatic breakdown. The discussion below separates what the molecule's chemistry suggests from what would require a specific measured value, and keeps storage and degradation framed around laboratory handling of the reagent.
The detail
A closer look
01
What the data does and does not specify
The provided record lists a pharmacokinetic and pharmacodynamic study of GHRP-2 (Pihoker et al., JCEM 1998; PMID 9543135) but supplies no explicit half-life, clearance, or volume-of-distribution figure. Accordingly, no specific elimination half-life value can be stated here; doing so would mean inventing a number the data does not contain. What can be said is that the peptide's pharmacokinetics have been characterized in the literature catalogued for this entry, and that any quantitative parameter would need to be read from that source rather than asserted from general reasoning. This section therefore treats half-life qualitatively and defers all numeric specifics to the cited pharmacokinetic characterization.
02
Structural features and general peptide stability
GHRP-2's sequence, D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, carries several non-natural and D-configured residues and a C-terminal amide. As a general principle within the synthetic growth hormone secretagogue class, incorporating D-amino acids and non-proteinogenic residues such as D-2-naphthylalanine, together with C-terminal amidation, tends to slow recognition by proteolytic enzymes relative to all-L natural peptides. These are general class-level expectations rather than GHRP-2-specific measured rates. The short hexapeptide length keeps the molecule compact, and the unusual residues are the same features that let it occupy the GHS-R1a activation domain. Where the data does not provide a measured degradation rate, these structural observations should be read as qualitative context, not as quantified stability values.
03
Storage-driven stability for laboratory reagents
In practical laboratory terms, the stability that matters most is reagent stability under storage rather than any in-solution clearance value. As with peptides generally, the lyophilized solid is the most durable form and is best kept cold and protected from moisture. Once reconstituted, the solution is the more labile state: refrigeration supports short-term use, freezing supports longer holding, and aliquoting limits damage from repeated freeze-thaw cycles. Using bacteriostatic water as the diluent adds preservative protection against microbial contamination during repeated sampling. These storage practices are the controllable determinants of how long a usable GHRP-2 stock remains intact for in-vitro work, and they apply regardless of the peptide's intrinsic in-solution pharmacokinetics.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. GHRP-2 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.